{"filing":{"accession_number":"0001193125-26-316067","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-22","primary_document":"fblg-20260722.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/fblg-20260722.htm"},"events":[{"id":20415,"run_id":18377,"accession_number":"0001193125-26-316067","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"FibroBiologics received a Staff Determination from Nasdaq on July 22, 2026, notifying the company of its determination to delist the company's securities from The Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2). The company's bid price closed below $1.00 for 30 consecutive business days (June 8–July 21, 2026) and is ineligible for the standard 180-day compliance period due to a prior reverse stock split. Unless the company appeals by July 29, 2026, delisting and suspension are scheduled for July 31, 2026. This is a quintessential delisting-risk disclosure under Item 3.01.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19771,"accession_number":"0001193125-26-316067","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"FibroBiologics received a Staff Determination from Nasdaq on July 22, 2026, notifying the company of its determination to delist the company's securities from The Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2). The company's bid price closed below $1.00 for 30 consecutive business days (June 8–July 21, 2026) and is ineligible for the standard 180-day compliance period due to a prior reverse stock split. Unless the company appeals by July 29, 2026, delisting and suspension are scheduled for July 31, 2026. This is a quintessential delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:06:44.232623+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19771,"accession_number":"0001193125-26-316067","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"FibroBiologics received a Staff Determination from Nasdaq on July 22, 2026, notifying the company of its determination to delist the company's securities from The Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2). The company's bid price closed below $1.00 for 30 consecutive business days (June 8–July 21, 2026) and is ineligible for the standard 180-day compliance period due to a prior reverse stock split. Unless the company appeals by July 29, 2026, delisting and suspension are scheduled for July 31, 2026. This is a quintessential delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:06:44.232623+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-07-24"}]}